StockNews.AI
IOVA
StockNews.AI
92 days

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit

1. A shareholder filed a class action against Iovance Biotherapeutics. 2. The class period spans May 9, 2024, to May 8, 2025. 3. Lawsuit claims misleading statements about Iovance's treatment timelines and patient drop-offs. 4. Higher costs and lower revenue cited as damaging factors in the lawsuit. 5. Investors may be eligible for compensation without upfront costs.

7m saved
Insight
Article

FAQ

Why Bearish?

The class action highlights operational mismanagement, likely leading to investor distrust. Historical lawsuits have often resulted in stock price declines, as seen with other biotech firms after similar claims.

How important is it?

The lawsuit touches on core business issues, implicating future revenue potential and overall investor confidence. It could deter new investments while lawsuits are unresolved.

Why Short Term?

Immediate concerns about IOVA's credibility may affect recent stock performance. Class actions typically generate rapid market reactions grading company reputations.

Related Companies

VRTXEDITCRSP
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2025. So What: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Iovance class action, go to https://rosenlegal.com/submit-form/?case_id=39482, call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) new Authorized Treatment Centers ("ATCs") were experiencing longer timelines to begin treating patients with Amtagvi; (2) Iovance's sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; (3) the foregoing dynamics led to higher costs and lower revenue because ATCs could not keep pace with manufactured product; and (4) as a result of the foregoing, Defendants' positive statements about Iovance's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. To join the Iovance class action, go to https://rosenlegal.com/submit-form/?case_id=39482 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:       Laurence Rosen, Esq.      Phillip Kim, Esq.      The Rosen Law Firm, P.A.      275 Madison Avenue, 40th Floor      New York, NY 10016      Tel: (212) 686-1060      Toll Free: (866) 767-3653      Fax: (212) 202-3827      [email protected]      www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News